---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-23-001085"
form_type: "8-K"
ticker: "FBIO"
cik: "0001429260"
company_name: "Fortress Biotech, Inc."
filed_at: "2023-02-09T23:59:59+00:00"
generated_at: "2026-06-19T19:54:34.389421+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Fortress Biotech prices $13.9M registered direct equity offering; warrants tied to subsidiary stakes

## Summary
- Issued 16.6M shares at $0.835/share for gross proceeds of ~$13.9M.
- Directors and officers purchased ~$3.3M of shares at same price, a premium to last close.
- Concurrent private placement grants rights to acquire ~3.5% equity in up to 20 new subsidiaries contingent on future deals.
- Contingent subsidiary securities exercisable for 10 years at FMV of subsidiary shares at time of trigger.
- Offering expected to close Feb 10, 2023; proceeds for working capital.

## SEC filing metadata
- accession: 0001558370-23-001085
- form_type: 8-K
- ticker: FBIO
- cik: 0001429260
- company_name: Fortress Biotech, Inc.
- filed_at: 2023-02-09T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1429260/000155837023001085/0001558370-23-001085-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1429260/000155837023001085/fbio-20230207x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-23-001085
- JSON: https://secwatch.observer/filing/0001558370-23-001085.json
- Plain text: https://secwatch.observer/filing/0001558370-23-001085.txt

## Key facts
- Material Agreements
  Fortress Biotech, Inc. entered into Securities Purchase Agreement with several institutional and accredited investors (effective 2023-02-07).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: several institutional and accredited investors
  - Effective: 2023-02-07
  source text: On February 7, 2023, Fortress Biotech, Inc. (the “ Company ”) entered into a Securities Purchase Agreement (the “ Securities Purchase Agreement ”) with each of several institutional and accredited investors (the “ Purchasers ”), pursuant to which the Company agreed to issue and sell an aggregate of 16,642,894 shares (the “ Shares ”) of common stock of the Company
  evidence_url: https://www.sec.gov/Archives/edgar/data/1429260/000155837023001085/0001558370-23-001085-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.